WaveMan
WaveMan · Company
TTRX · Turn Therapeutics Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

TTRX Turn Therapeutics (TTRX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0002023016
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
14
13F, latest reported quarter

Turn Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Turn Therapeutics Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Chaudhary Zuraiz
See Remarks
BUY
2025-12-12 SEC
2,500
$8.8K
+238.3%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Nov 21, 2025.
  • -1.1% median (+1.8% mean) 90-day return after 4 previous buys.
  • The trade is 20.0% of the 12,500 shares held after it.
  • 1 other insider bought within 30 days.
  • 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Chaudhary Zuraiz bought about $8.8K of TTRX on Dec 12, 2025; 1 other insider bought within 30 days and 14 funds added in the latest 13F quarter.
GOLDEN ARTHUR F
Director
BUY
2025-11-25 SECtraded 2025-11-24
9,868
$33.9K
+206.5%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Nov 21, 2025.
  • -1.1% median (-1.1% mean) 90-day return after 2 previous buys.
  • The trade is 16.3% of the 60,602 shares held after it.
  • 1 other insider bought within 30 days.
  • 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director GOLDEN ARTHUR F bought about $33.9K of TTRX on Nov 24, 2025; 1 other insider bought within 30 days and 14 funds added in the latest 13F quarter.
GOLDEN ARTHUR F
Director
BUY
2025-11-24 SECtraded 2025-11-21
20,532
$58.9K
+215.8%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Oct 23, 2025.
  • The trade is 40.5% of the 50,734 shares held after it.
  • 2 other insiders bought within 30 days.
  • 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director GOLDEN ARTHUR F bought about $58.9K of TTRX on Nov 21, 2025; 2 other insiders bought within 30 days and 14 funds added in the latest 13F quarter.
Chaudhary Zuraiz
See Remarks
BUY
2025-11-21 SEC
1,000
$3.3K
+197.7%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Nov 20, 2025.
  • -6.3% median (+1.1% mean) 90-day return after 3 previous buys.
  • The trade is 10.0% of the 10,000 shares held after it.
  • 2 other insiders bought within 30 days.
  • 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Chaudhary Zuraiz bought about $3.3K of TTRX on Nov 21, 2025; 2 other insiders bought within 30 days and 14 funds added in the latest 13F quarter.
Chaudhary Zuraiz
See Remarks
BUY
2025-11-21 SECtraded 2025-11-20
1,450
$3.8K
+197.7%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Nov 17, 2025.
  • -7.4% median (-7.4% mean) 90-day return after 2 previous buys.
  • The trade is 16.1% of the 9,000 shares held after it.
  • 2 other insiders bought within 30 days.
  • 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Chaudhary Zuraiz bought about $3.8K of TTRX on Nov 20, 2025; 2 other insiders bought within 30 days and 14 funds added in the latest 13F quarter.
9 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 4 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
14 funds bought in last quarter
below 75% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
4.0% of the float short (float per yahoo 2026-10-27) · 4.2 days to cover · settled 2026-10-15
below 69% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch TTRX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+110.5%12M
-45%+40%+125%+210%2025-102025-122026-022026-042026-062026-082026-10 2025-10-23 · GOLDEN ARTHUR F bought $100.0K2025-10-23 · Chesed Abraham bought $65.7K2025-11-21 · GOLDEN ARTHUR F bought $58.9K2025-11-24 · GOLDEN ARTHUR F bought $33.9K2025-10-23 · Chaudhary Zuraiz bought $25.0K2025-11-17 · Chaudhary Zuraiz bought $9.1K2025-12-12 · Chaudhary Zuraiz bought $8.8K2025-11-20 · Chaudhary Zuraiz bought $3.8K2025-11-21 · Chaudhary Zuraiz bought $3.3K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns TTRX: institutional holders (13F)

13F holdings, latest reported quarter
SteelPeak Wealth, LLC
249,456 sh
$1.8M
IEQ CAPITAL, LLC
227,396 sh
$1.7M
DDFG, Inc
107,829 sh
$787.2K
VANGUARD CAPITAL MANAGEMENT LLC
74,301 sh
$542.4K
Wellington Shields & Co., LLC
65,732 sh
$479.8K

Congress trades in TTRX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

TTRX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

TTRX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$264.5K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$17.2K position · as of 2026-06-30
0.0%
Victory Extended Market Index Fund
$10.4K position · as of 2026-07-31
0.0%
Fidelity Nasdaq Composite Index Fund
$89.1K position · as of 2026-05-31
0.0%
VANGUARD BALANCED INDEX FUND
$72.2K position · as of 2026-06-30
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$458.1K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
1 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Multi-phase
1 active
What changed recently
A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and
2026-09-05 · Completion moved 2026-07-10 → 2027-01-20
PHASE2,PHASE3
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 14 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

TTRX financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
8.83x
long-term debt only, 2026-06-30; equity 2026-06-30
Cash flow to debt
-0.71x
TTM operating cash flow over long-term debt only, 2026-06-30
Return on equity
-686.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-49.8%
TTM net income over ending balance 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-85.2%
operating income (EBIT proxy) over ending balance 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$306.5M
market value at close 2026-10-27 on 2026-08-12 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-12
Operating income-$5.9M-$1.8M
Net income-$3.2M-$1.8M
EPS (diluted)-0.12-0.07
Operating cash flow-$2.6M-$1.4M
Cash$4.0M$498.3K
SEC XBRL, fiscal years, as known on 2026-10-28

TTRX Stock Sonar score 4/7 axes

Find similar shapesCompare

TTRX ranks highest on risk and compliance (63rd percentile) and financial health (29th), and lowest on institutional and government (25th), among Pharma & Biotech peers.

Profitability
27
Inputs
  • Return on equity-686.3% · 6 pct, sector of 545
  • Return on assets-49.8% · 44 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-85.2% · 30 pct, sector of 576
Financial health
29
Inputs
  • Debt to equity8.83x · 2 pct, sector of 352
  • Cash flow to debt-0.71x · 56 pct, sector of 371
Institutional and government
25
Inputs
  • Funds adding, latest quarter14 · 25 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
63
Inputs
  • Short interest, % of float+4.0% · 63 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Growth, Insider conviction, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies